1. Market Research
  2. > Appetite (Eating) Disorders - Pipeline Review, H2 2013

Appetite (Eating) Disorders - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 42 pages

Appetite (Eating) Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Appetite (Eating) Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Appetite (Eating) Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Appetite (Eating) Disorders. Appetite (Eating) Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Appetite (Eating) Disorders.
- A review of the Appetite (Eating) Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Appetite (Eating) Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Appetite (Eating) Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Appetite (Eating) Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Appetite (Eating) Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Appetite (Eating) Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Appetite (Eating) Disorders 7
Appetite (Eating) Disorders Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Appetite (Eating) Disorders Therapeutics - Products under Development by Companies 12
Companies Involved in Appetite (Eating) Disorders Therapeutics Development 13
GlaxoSmithKline plc 13
INSYS Therapeutics, Inc. 14
Global Health Ventures Inc. 15
Omeros Corporation 16
Medisyn Technologies, Inc. 17
Kuhnil Pharmaceutical Co., Ltd. 18
MAKScientific, LLC 19
Appetite (Eating) Disorders - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
GSK-1521498 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
GPR101 Antagonist - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
dronabinol - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
cianidanol - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
KI-1003 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Dopamine Inhibitor - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Drug Targeting GPR82 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
AM-6527 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Appetite (Eating) Disorders Therapeutics - Drug Profile Updates 34
Appetite (Eating) Disorders Therapeutics - Dormant Products 35
Appetite (Eating) Disorders - Product Development Milestones 36
Featured News and Press Releases 36
Aug 08, 2012: Lightlake Therapeutics Announces Positive Preliminary Phase II Clinical Trial Results Of Binge Eating Disorder Treatment 36
May 03, 2012: Lightlake Announces Positive Preliminary Phase II Trial Results Of Binge Eating Disorder Treatment Using Naloxone 37
Apr 26, 2012: Shire Reports Positive Top-Line Results From Phase II Study Of Vyvanse In Adults With Binge Eating Disorder 38
Mar 02, 2011: Omeros Unlocks Orphan GPCRs Linked To Pancreatic Cancer And Cognitive Disorders 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42



List of Tables

Number of Products Under Development for Appetite (Eating) Disorders, H2 2013 7
Products under Development for Appetite (Eating) Disorders - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
GlaxoSmithKline plc, H2 2013 13
INSYS Therapeutics, Inc., H2 2013 14
Global Health Ventures Inc., H2 2013 15
Omeros Corporation, H2 2013 16
Medisyn Technologies, Inc., H2 2013 17
Kuhnil Pharmaceutical Co., Ltd., H2 2013 18
MAKScientific, LLC, H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 24
Appetite (Eating) Disorders Therapeutics - Drug Profile Updates 34
Appetite (Eating) Disorders Therapeutics - Dormant Products 35



List of Figures

Number of Products under Development for Appetite (Eating) Disorders, H2 2013 7
Products under Development for Appetite (Eating) Disorders - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Discovery and Pre-Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 20
Assessment by Route of Administration, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Molecule Type, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 24



Companies Mentioned

GlaxoSmithKline plc
INSYS Therapeutics, Inc.
Global Health Ventures Inc.
Omeros Corporation
Medisyn Technologies, Inc.
Kuhnil Pharmaceutical Co., Ltd.
MAKScientific, LLC

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.